Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F
Open Access
- 6 October 2014
- journal article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 211 (11), 2213-2230
- https://doi.org/10.1084/jem.20131371
Abstract
The majority of patients with myeloproliferative neoplasms (MPNs) carry a somatic JAK2-V617F mutation. Because additional mutations can precede JAK2-V617F, it is questioned whether JAK2-V617F alone can initiate MPN. Several mouse models have demonstrated that JAK2-V617F can cause MPN; however, in all these models disease was polyclonal. Conversely, cancer initiates at the single cell level, but attempts to recapitulate single-cell disease initiation in mice have thus far failed. We demonstrate by limiting dilution and single-cell transplantations that MPN disease, manifesting either as erythrocytosis or thrombocytosis, can be initiated clonally from a single cell carrying JAK2-V617F. However, only a subset of mice reconstituted from single hematopoietic stem cells (HSCs) displayed MPN phenotype. Expression of JAK2-V617F in HSCs promoted cell division and increased DNA damage. Higher JAK2-V617F expression correlated with a short-term HSC signature and increased myeloid bias in single-cell gene expression analyses. Lower JAK2-V617F expression in progenitor and stem cells was associated with the capacity to stably engraft in secondary recipients. Furthermore, long-term repopulating capacity was also present in a compartment with intermediate expression levels of lineage markers. Our studies demonstrate that MPN can be initiated from a single HSC and illustrate that JAK2-V617F has complex effects on HSC biology.Keywords
This publication has 64 references indexed in Scilit:
- Dynamic variation in cycling of hematopoietic stem cells in steady state and inflammationThe Journal of Experimental Medicine, 2011
- Distinct Clinical Phenotypes Associated with JAK2V617F Reflect Differential STAT1 SignalingCancer Cell, 2010
- Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor CellsCancer Cell, 2010
- Heterogeneity and hierarchy within the most primitive hematopoietic stem cell compartmentThe Journal of Experimental Medicine, 2010
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem CellsCell, 2009
- Mutation in TET2 in Myeloid CancersThe New England Journal of Medicine, 2009
- Maximal STAT5-Induced Proliferation and Self-Renewal at Intermediate STAT5 Activity LevelsMolecular and Cellular Biology, 2008
- Efficient Transplantation via Antibody-Based Clearance of Hematopoietic Stem Cell NichesScience, 2007
- Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potentialGenes & Development, 2007
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005